Mesenchymal stem cells are multipotent stromal cells with well-documented immunomodulatory, anti-inflammatory, and regenerative properties. In the context of autism spectrum disorder, MSC-based treatment protocols aim to support the body's own regulatory and repair mechanisms — particularly in areas where emerging research has identified biological disruptions that may contribute to developmental and behavioral challenges.
The MSCs used in our protocols are derived from umbilical cord tissue, specifically Wharton's Jelly — a connective tissue rich in young, highly viable mesenchymal cells. These cells are chosen for their potent paracrine activity: their ability to release growth factors, anti-inflammatory cytokines, and extracellular vesicles that influence surrounding cells and tissues. All cell products are sourced from GMP-certified laboratories with comprehensive batch testing, characterization, and traceability documentation.
It is important for families to understand that stem cell therapy for autism remains investigational. Published preclinical studies and early-phase clinical research have shown signals of potential benefit in areas such as immune modulation, neuroinflammatory support, and developmental progress — but large-scale randomized controlled trials are still ongoing. We present the current state of evidence transparently and help families make informed decisions based on their child's unique biological and developmental situation.